{"id":"NCT00889330","sponsor":"Vistakon Pharmaceuticals","briefTitle":"Safety and Efficacy Study of a Eye Drop for Eye Allergy","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2009-05","completion":null,"firstPosted":"2009-04-28","resultsPosted":"2011-12-08","lastUpdate":"2015-03-06"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"alcaftadine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"alcaftadine ophthalmic solution","type":"EXPERIMENTAL"},{"label":"inactive ophthalmic solution vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.","primaryOutcome":{"measure":"Ocular Itching at Visit 3 (Day 0) at 7 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation.","timeFrame":"Visit 3 (Day 0) 16 hours post-dose, at up to 7 minutes following Allergen Challenge","effectByArm":[{"arm":"Alcaftadine Ophthalmic Solution","deltaMin":0.69,"sd":0.691},{"arm":"Inactive Vehicle Ophthalmic Solution","deltaMin":2.27,"sd":0.97}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["21250860"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":[]}}